Cargando…

Enhancement of SARS-CoV-2 vaccine-induced immunity by a Toll-like receptor 7 agonist adjuvant

Detalles Bibliográficos
Autores principales:	Li, Gen, Yu, Meixing, Ke, Qiong, Sun, Jing, Peng, Yanwen, Xiong, Chuanfeng, Monteiro, Olivia, Zhao, Jincun, Xiang, Andy P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206358/ https://www.ncbi.nlm.nih.gov/pubmed/37225686 http://dx.doi.org/10.1038/s41392-023-01485-6

Ejemplares similares

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
por: Bhagchandani, Sachin, et al.
Publicado: (2021)

Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine
por: Gableh, Fateme, et al.
Publicado: (2016)

Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants
por: Kumar, Sudeep, et al.
Publicado: (2019)

Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects
por: Zhang, Shuquan, et al.
Publicado: (2022)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases
por: Yang, Jing-Xing, et al.
Publicado: (2022)

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
por: Hotz, Christian, et al.
Publicado: (2012)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

The Toll‐like receptor 7 agonist imiquimod increases ethanol self‐administration and induces expression of Toll‐like receptor related genes
por: Lovelock, Dennis F., et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists
por: Salyer, Alex C. D., et al.
Publicado: (2018)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity
por: Seya, Tsukasa, et al.
Publicado: (2015)

Combining vasculature disrupting agent and toll-like receptor 7/8 agonist for cancer therapy
por: Seth, Anushree, et al.
Publicado: (2016)

Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
por: Angelopoulou, Athina, et al.
Publicado: (2020)

Synthetic Toll-like Receptors 7 and 8 Agonists: Structure–Activity Relationship in the Oxoadenine Series
por: Evans, Jay T., et al.
Publicado: (2019)

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
por: Patinote, Cindy, et al.
Publicado: (2020)

Surface Immunogenic Protein of Streptococcus Group B is an Agonist of Toll-Like Receptors 2 and 4 and a Potential Immune Adjuvant
por: Diaz-Dinamarca, Diego A., et al.
Publicado: (2020)

Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies
por: Yu, Hui, et al.
Publicado: (2013)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome
por: Petes, Carlene, et al.
Publicado: (2017)

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Role of Toll-like Receptors in Adjuvant-Augmented Immune Therapies
por: Seya, Tsukasa, et al.
Publicado: (2006)

Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists
por: Debnath, Sashi, et al.
Publicado: (2022)

SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability
por: Huang, Hong, et al.
Publicado: (2023)

Toll-like receptor 2 agonists inhibit human fibrocyte differentiation
por: Maharjan, Anu S, et al.
Publicado: (2010)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
por: Li, Wei, et al.
Publicado: (2022)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B
por: Wildum, Steffen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a0165q56tkavoufhvp06qefc74